• Facebook
  • LinkedIn
  • Twitter
  • Instagram
  • Pinterest
  • Youtube
  • Mail
  • Rss
  • Log In
    • Register
Contacts us @ MediPr.org
Medical Writer Agency | 醫學作家香港 | 醫學寫作 | MediPR | MediPaper Hong Kong
  • MDnews
  • About [‘mediPr]
  • Search
  • Menu Menu

Non-Sponsored Content

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail


MEDICAL NEWS ASIA

Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

By: Stijn van den Borne, MSc | Last updated: 26th April 2019 | In: Hernia Repair, Internal Medicine, Medical News Asia, News, Surgery

Article Keywords

inguinal disruption, NovusScientific, surgical matrix, surgical mesh, TIGR

UPPSALA, Sweden, April 24, 2019 /PRNewswire/ — Researchers of the Erasmus University Medical Center in Rotterdam − the Netherlands, consider that the synthetic and fully resorbable TIGR® Matrix surgical mesh (Novus Scientific AB, Uppsala − Sweden) may reduce frequent risks related to the surgical repair of Sportsman’s hernia.

Inguinal disruption – also commonly referred to as Sportman’s hernia – is a group name for painful injuries in the groin area caused by repetitive strain and strenuous training. It occurs in up to 28% of high-performing athletes, and may occasionally affect non-athletes.1Sheen AJ, et al. Br J Sports Med. 2014;48(14):1079-87.,2Nam A & Brody F. J Am Coll Surg. 2008;206(1):154-64.

Unlike true hernias, a Sportsman’s hernia does not include the bulging of organs or fatty tissue through a hole in the weakened muscle or tendons of the abdomen.1Sheen AJ, et al. Br J Sports Med. 2014;48(14):1079-87.

The initial treatment of Sportman’s hernia includes physical therapy, rehabilitation programs, sometimes in combination with steroid injections.1Sheen AJ, et al. Br J Sports Med. 2014;48(14):1079-87.

“A treatment option for patients not responding to initial therapy is placement of a permanent mesh by minimally invasive procedure,” explained Prof. Johan Lange of the Department of Surgery at the Erasmus University MC. “Such mesh aims to support the damaged tendons and absorbs pressure during physical exercise.”

Despite the promising results and often fast resumption of sport activities by the patient after the surgical repair, there have been several reports of chronic pain and other severe side effects related to permanent mesh placement.3Doctor HG. J Minim Access Surg. 2006;2(3):110-6.

According to Prof. Gert-Jan Kleinrensink of the Department of Neuroscience at the Erasmus University MC, permanent, non-absorbable meshes can cause serious complications, including chronic post-operative pain. “We are very interested to evaluate whether a slowly resorbable surgical mesh, such as the TIGR® Matrix, could help prevent these issues.”

The researchers of the R.E.P.A.I.R study group, who have published around 200 peer-reviewed articles on the use of surgical meshes in various procedures, are now planning a study to investigate the usefulness of the TIGR® Matrix surgical mesh for the treatment of inguinal disruption.

About the TIGR®Matrix

TIGR®Matrix is the first long-term resorbable, 100% synthetic, surgical mesh. Its unique technology consisting of dual-stage degradation and full resorption, paired with ease of use, is a significant step forward in surgical mesh technology.

The fast-degrading part improves the mesh’ flexibility and stretchability, provides extra strength during the immediate healing phase, and gradually absorbs during the first four months. The slow-degrading part of the mesh provides optimal strength for up to nine months with complete resorption in approximately three years. TIGR®Matrix uses 100% synthetic polymers that are well documented, clinically proven, and commonly used in medical devices since the 1970s.

About Novus Scientific

Novus Scientific AB (www.novusscientific.com) develops, manufactures and markets resorbable implants that help the body’s own healing. The headquarter, research and production facilities are located in Uppsala, Sweden.

Source

1. Sheen AJ, et al. Br J Sports Med. 2014;48(14):1079-87.
2. Nam A & Brody F. J Am Coll Surg. 2008;206(1):154-64.
3. Doctor HG. J Minim Access Surg. 2006;2(3):110-6.


Newsletter Sign-Up

Do you like our content? Subscribe to our non-intrusive newsletter today! We promise we won’t be spammy.

Newsletter Sign-Up


YOU MAY ALSO LIKE

Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

https://ftp.medi-paper.com/wp-content/uploads/2019/01/Erasmus-University-MC-investigating-a-new-surgical-matrix-to-reduce-post-operative-complications.jpg 900 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-01-16 22:58:582019-01-16 23:09:21Erasmus University MC investigating a new surgical matrix to reduce post-operative complications
TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

https://ftp.medi-paper.com/wp-content/uploads/2018/12/TIGR®Matrix-shows-promising-results-when-used-for-incisional-hernia-prevention-in-septic-patients-undergoing-laparoscopy.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-04 21:28:362018-12-05 11:50:08TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy
Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

https://ftp.medi-paper.com/wp-content/uploads/2018/11/Fully-resorbable-synthetic-matrix-offers-improved-safety-for-breast-cancer-patients-undergoing-immediate-breast-reconstruction.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-21 16:41:202018-12-04 21:34:06Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction
innovent biologics anti-pd1 sintilimab plus biosimilar bevacizumab receive ind status by china nmpa

Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA

https://ftp.medi-paper.com/wp-content/uploads/2018/10/innovent-biologics-anti-pd1-sintilimab-plus-biosimilar-bevacizumab-receive-ind-status-by-china-nmpa-e1539612467836.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-15 22:26:302018-10-17 11:29:45Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA
PreviousNext
Erasmus University MC investigating a new surgical matrix to reduce post-operative complications
16th January 2019

Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy
4th December 2018

TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

© Copyright 2019 MediPaper Medical Communications Ltd. – Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail

YOU MAY ALSO LIKE

Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

https://ftp.medi-paper.com/wp-content/uploads/2019/01/Erasmus-University-MC-investigating-a-new-surgical-matrix-to-reduce-post-operative-complications.jpg 900 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-01-16 22:58:582019-01-16 23:09:21Erasmus University MC investigating a new surgical matrix to reduce post-operative complications
TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

https://ftp.medi-paper.com/wp-content/uploads/2018/12/TIGR®Matrix-shows-promising-results-when-used-for-incisional-hernia-prevention-in-septic-patients-undergoing-laparoscopy.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-04 21:28:362018-12-05 11:50:08TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy
Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

https://ftp.medi-paper.com/wp-content/uploads/2018/11/Fully-resorbable-synthetic-matrix-offers-improved-safety-for-breast-cancer-patients-undergoing-immediate-breast-reconstruction.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-21 16:41:202018-12-04 21:34:06Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction
innovent biologics anti-pd1 sintilimab plus biosimilar bevacizumab receive ind status by china nmpa

Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA

https://ftp.medi-paper.com/wp-content/uploads/2018/10/innovent-biologics-anti-pd1-sintilimab-plus-biosimilar-bevacizumab-receive-ind-status-by-china-nmpa-e1539612467836.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-15 22:26:302018-10-17 11:29:45Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA
CAR-T axicabtagene ciloleucel granted Orphan Drug Designation for B-Cell Lymphoma by the Japan MHLW

CAR-T axicabtagene ciloleucel granted Orphan Drug designation for B-Cell Lymphoma by the Japan MHLW

https://ftp.medi-paper.com/wp-content/uploads/2018/10/CAR-T-axicabtagene-ciloleucel-granted-Orphan-Drug-Designation-for-B-Cell-Lymphoma-by-the-Japan-MHLW.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-05 15:24:252018-10-17 11:23:17CAR-T axicabtagene ciloleucel granted Orphan Drug designation for B-Cell Lymphoma by the Japan MHLW
Quizartinib Receives Orphan Drug Designation for FLT3-Mutated AML in Japan

Quizartinib receives Orphan Drug designation for FLT3-mutated AML in Japan

https://ftp.medi-paper.com/wp-content/uploads/2018/09/Quizartinib-Receives-Orphan-Drug-Designation-for-FLT3-Mutated-AML-in-Japan.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-12 22:21:342018-09-12 22:21:34Quizartinib receives Orphan Drug designation for FLT3-mutated AML in Japan
CAR-TCR Summit 2018 Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer© Royaltystockphoto / 123RF Stock Photo

CAR-TCR Summit 2018: Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer

https://ftp.medi-paper.com/wp-content/uploads/2018/09/CAR-TCR-Summit-2018-Preliminary-first-in-human-data-with-CAR-Claudin18.2-T-in-gastric-and-pancreatic-cancer.jpg 1054 1505 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-09 09:38:282018-09-09 09:38:28CAR-TCR Summit 2018: Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer
DRIVER connects cancer patients in China and the United States to the best care© Kentoh / 123RF Stock Photo

DRIVER connects cancer patients in China and the United States to the best care

https://ftp.medi-paper.com/wp-content/uploads/2018/09/DRIVER-connects-cancer-patients-in-China-and-the-United-States-to-the-best-care.jpg 994 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-07 21:45:362018-09-07 21:45:36DRIVER connects cancer patients in China and the United States to the best care
First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation© luchschen / 123RF Stock Photo

First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

https://ftp.medi-paper.com/wp-content/uploads/2018/08/First-in-Class-Oncology-Vaccine-BIL06v-Starts-Phase-1-Evaluation.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-22 11:48:172018-08-27 09:35:59First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation
PolyU Researcher Develop Novel Self-fitting Scaffold for Bone-Regeneration©Polytech University Hong Kong

PolyU Researchers Develop Novel Self-fitting Scaffold for Bone-Regeneration

https://ftp.medi-paper.com/wp-content/uploads/2018/08/PolyU_bone_regeneration-e1534396913248.jpg 788 1184 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-16 13:24:162018-08-16 19:14:03PolyU Researchers Develop Novel Self-fitting Scaffold for Bone-Regeneration
Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China©Alex011973 / 123RF Stock Photo

Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China

https://ftp.medi-paper.com/wp-content/uploads/2018/08/Pan-EGFR-TKI-pirotinib-has-commenced-into-Phase-II-clinical-testing-in-China.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-13 23:09:022018-09-07 21:59:21Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China
PreviousNext
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply Cancel reply

You must be logged in to post a comment.

© Copyright 2019 MediPaper Medical Communications Ltd. – Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

Therapeutic Areas

Login

or
Login with Google
Login with Facebook
Login with Twitter
Login with LinkedIn
  • Register
  • Lost your password?

Or, sign up for our newsletter


Interesting links

Here are some interesting links for you! Enjoy your stay :)
© 2016-2022 MediPaper Medical Communications Ltd. | Website by [’mediPr] | 醫學作家香港 | Privacy Policy | Cookie Policy
  • Facebook
  • LinkedIn
  • Twitter
  • Instagram
  • Pinterest
  • Youtube
  • Mail
  • Rss
Pembrolizumab plus axitinib FDA approved for the first-line treatment of advanced...Ivosidenib FDA-approved as first-line treatment for AML patients with IDH1 ...
Scroll to top

This site uses cookies to improve your experience. By continuing to browse the site, you are agreeing to our use of cookies.

OKPrivacy Settings

Cookies and Privacy on medi-paper.com



Cookie Policy

How MediPaper uses cookies is explained in our Cookie Policy

Privacy Policy

Read MediPaper's Privacy Policy

Google Analytics cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Vimeo and Youtube video embeds:

Accept settingsHide notification only
Copy link
CopyCopied
Powered by Social Snap
MediPaper Medical Communications Agency Hong Kong Blog